Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PXL 770

Next Previous
Drug Profile

PXL 770

Alternative Names: PXL-770

Latest Information Update: 28 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Poxel
  • Class Antihyperglycaemics; Cardiovascular therapies; Hepatoprotectants; Heterocyclic compounds; Naphthalenes; Potassium compounds; Pyridines; Small molecules; Urologics
  • Mechanism of Action AMP activated protein kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adrenoleucodystrophy; Autosomal dominant polycystic kidney disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Adrenoleucodystrophy; Non-alcoholic fatty liver disease
  • Phase I Autosomal dominant polycystic kidney disease
  • No development reported Cardiomyopathies
  • Discontinued Metabolic disorders; Type 2 diabetes mellitus

Most Recent Events

  • 28 Jan 2026 No recent reports of development identified for preclinical development in Cardiomyopathies in France
  • 24 Sep 2025 Discontinued - Phase-I for Metabolic disorders (In volunteers) in United Kingdom (PO) (Poxel pipeline, September 2025)
  • 16 Dec 2024 Poxel withdrwn a phase-II clinical trials in Adrenoleucodystrophy (In adults, In the elderly) in Germany, Netherlands, France, Spain, Belgium, Sweden, Denmark and Italy (PO) due to lack of funding to initiate the trial (NCT05146284)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top